Agreed. The CHF is the one that is hard to work out. On one hand there is a reduction in death and life threatening incidents like stroke and heart attack which has an immediate benifit but there is also the halt on disease progression which need longer trail time to demonstrate.
CLBP shows an immediate reduction on opioid dependence which could only need 12 month trail and has a system to utilise in surgcentre clinics for recruitment and observations if not seen as a conflicting resource.
other then paediatric AGVHD u.s. revenue with some small off label revenue to possibly 2hcy22 we still need to partner for the bigger indication of CHF.
I can't see significant share price increases until both CLBP trail started with achievable p.e. and CHF partnering and trail established.
still alot of potential but need more information which could be known by the end of the year.
your thoughts?
Rem-L needed Yesterday, page-6
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.32 |
Change
-0.025(1.86%) |
Mkt cap ! $1.507B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.35 | $1.31 | $2.699M | 2.040M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 34995 | $1.32 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.33 | 10374 | 2 |
View Market Depth
| Last trade - 16.10pm 31/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |